This review examines the evidence behind Plenity and how to read it. We did not establish a current manufacturer offer, price or supply arrangement from the sources checked for this article. That leaves a practical access question unanswered; it does not establish that the product has been discontinued.
Keep two sets of notes as you read: what the study measured, and what you would need to know about a product offered today. Mixing those questions makes an old research result sound like a current recommendation. A useful review should help you separate them.
Start with the product identity
The historical FDA device record describes Plenity as a prescription hydrogel aid to weight management, used with diet and exercise by adults with BMI 25–40.
This is a product evidence review, separate from our directory of telehealth services. When comparing reviews, first match the exact product name and preparation. Then identify whether the page is discussing a product, a clinic or an entire care package. Those are different objects of evaluation; a favorable account of one does not answer questions about the others.
Keep the comparison group beside the result
GLOW randomized 436 participants to Plenity or sham capsules, with diet and exercise. At day 171, mean weight loss was 6.4% versus 4.4%; the prespecified three-percentage-point superiority margin was missed. The co-primary performance goal required more than 35% of Plenity participants to lose at least 5% of body weight. It was met: responder proportions were 58.6% with Plenity versus 42.2% with sham.
A group average and the proportion crossing a threshold answer different questions. Read the outcome definition before interpreting the number. Keep the comparison group, follow-up period and analysis population beside it in your notes. Neither kind of result locates an individual reader within the range of possible experiences.
A result also needs to be judged against the test the investigators set in advance. A difference between groups and success against a specified margin are separate statements. Retaining both statements is more informative than reducing a study to a single favorable or unfavorable headline.
Ask who is represented in the analysis
GLOW enrolled adults aged 22–65 with BMI 27–40, narrower than the label’s BMI 25–40. Enrollment below BMI 30 required type 2 diabetes, dyslipidemia or hypertension. The primary intention-to-treat analysis used multiple imputation for missing data. Withdrawals and limited population representation constrain interpretation; the extension selected completers who had already lost weight.
When reading any follow-up report, ask who entered that analysis and who is no longer represented. A result for participants who stayed in a study answers a narrower question than a result that accounts for everyone originally assigned. Look for that distinction before treating a later observation as a prediction of durability.
Our guide to missing trial records offers another example of reading an analysis carefully. It is related reading about method, not a comparison between the treatments. Comparing percentages from unrelated studies would require examining their populations, controls, timing and outcome definitions first.
Turn the evidence into a clinical conversation
The FDA record includes gastrointestinal adverse events and contraindications, including pregnancy and specified ingredient allergies.
Bring the exact product information and your medication list to that conversation. Ask what would make the product inappropriate for you, what uncertainties matter in your circumstances and whom to contact about a concern. A review cannot complete that assessment. It also cannot replace the instructions supplied for an actual prescription.
Establish current access separately
Before relying on an old buying guide, seek a dated answer identifying the current product, responsible seller or distributor, supply status and complete price. Keep that answer with the offer you are considering. An archived research document cannot confirm that a particular seller has stock or that its terms apply to you.
If an offer cannot be tied to a clear product identity, leave the comparison unfinished rather than filling the gap with a familiar brand name. We have no current purchasing recommendation to make from this review.
How to use the source below
The FDA record lists November 15, 2018 as the submission-received date.
That is not the date of this review, and we have not established the document’s original publication or revision date. The source entry records when it was checked. Keeping those dates distinct helps you see what is historical and what was actually examined for this article.
Sources and review method
This is a review of a public regulator document and the limits of the available information. We did not test the product, verify a current commercial supply, or conduct a patient study. This article has not received clinician review.
- FDA device recordDocument checked